Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Aurélien Marabelle, MD, PhD, clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Initial findings from an ongoing phase 1/1b trial (NCT04234113), which evaluated SO-C101 as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced or metastatic solid tumors, were presented during the 2020 SITC Annual Meeting. SO-C101 demonstrated encouraging efficacy signals with a manageable safety profile in 1 patient who was refractory to anti–PD-1 therapy. The patient derived a partial response to the treatment with 20% shrinkage of target lesions at 6 weeks and 49% shrinkage at 12 weeks.
These findings suggest that SO-C101 could have clinical utility in patients who are refractory to anti–PD-1 therapy, says Marabelle. Moreover, SO-C101 has the potential to reverse PD-1 inhibitor resistance by amplifying a patient’s antitumor immune response, he adds.
These results corroborated preclinical findings and suggest an additional signal that cytokine therapies beyond interleukin-15 are promising, Marabelle explains. Further research is needed to determine the optimal use of these agents with regard to sequencing, dosing, and timing of infusions, concludes Marabelle.